- DKK131.15bn
- DKK103.78bn
- DKK16.47bn
- 90
- 19
- 18
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 22.01 | ||
| PEG Ratio (f) | 1.01 | ||
| EPS Growth (f) | 27.98% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.15 | ||
| Price to Tang. Book | 4.16 | ||
| Price to Free Cashflow | 18.72 | ||
| Price to Sales | 7.96 | ||
| EV to EBITDA | 18.38 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.22% | ||
| Return on Equity | 14.78% | ||
| Operating Margin | 32.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | DKKm | 5,366 | 10,111 | 8,417 | 14,505 | 16,474 | 19,671.38 | 23,321.69 | 40.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +43.45 | +113.03 | -38.25 | +85.49 | -20.5 | +25.85 | +31.86 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Directors
- Deirdre Connelly CHM (60)
- Jan van de Winkel CEO (60)
- Anthony Pagano CFO (43)
- Anthony Mancini COO (50)
- Tahamtan Ahmadi EVP (48)
- Judith Klimovsky EVP (64)
- Birgitte Stephensen SVP (60)
- Martine van Vugt SVP (50)
- Rima Nassar DRC (67)
- Anders Pedersen DRC (69)
- Peter Storm Kristensen DRC (46)
- Mijke Zachariasse DRC (47)
- Pernille Erenbjerg IND (53)
- Rolf Hoffmann IND (62)
- Paolo Paoletti IND (70)
- Jonathan Peacock IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 11th, 1998
- Public Since
- October 1st, 2000
- No. of Shareholders
- 85,685
- No. of Employees
- 2,204
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange - Copenhagen- Shares in Issue
- 65,378,794
- Address
- Kalvebod Brygge 43, KOEBENHAVN V, 1560
- Web
- https://www.genmab.com/
- Phone
- +45 null70202728
- Contact
- Andrew Carlsen
- Auditors
- PricewaterhouseCoopers
Upcoming Events for GMAB
Q2 2024 Genmab A/S Earnings Release
Similar to GMAB
Gubra A/S
OMX Nordic Exchange - Copenhagen
Orphazyme A/S
OMX Nordic Exchange - Copenhagen
ViroGates A/S
OMX Nordic Exchange - Copenhagen
Zealand Pharma A/S
OMX Nordic Exchange - Copenhagen
FAQ
What is the Genmab A/S share price?
As of Today at 19:09 UTC, shares in Genmab A/S are trading at DKK2,006.00. This share price information is delayed by 15 minutes.
How has the Genmab A/S share price performed this year?
Shares in Genmab A/S last closed at DKK2,006.00 and the price had moved by -27.84% over the past 365 days. In terms of relative price strength the Genmab A/S share price has underperformed the FTSE Global All Cap Index by -32.26% over the past year.
What are the analyst and broker recommendations for Genmab A/S?
The overall consensus recommendation for Genmab A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Genmab A/S dividend yield?
Genmab A/S does not currently pay a dividend.
Does Genmab A/S pay a dividend?
Genmab A/S does not currently pay a dividend.
When does Genmab A/S next pay dividends?
Genmab A/S does not currently pay a dividend.
How do I buy Genmab A/S shares?
To buy shares in Genmab A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Genmab A/S?
As of the previous close price of DKK2,006.00, shares in Genmab A/S had a market capitalisation of DKK131.15bn.
Where are Genmab A/S shares listed?
Here are the trading details for Genmab A/S:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: GMAB
What kind of share is Genmab A/S?
Based on an overall assessment of its quality, value and momentum Genmab A/S is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Genmab A/S share price forecast for 2024?
The analyst consensus target price for shares in Genmab A/S is DKK2,693.24. That is 34.26% above the last closing price of DKK2,006.00.
Analysts covering Genmab A/S currently have a consensus Earnings Per Share (EPS) forecast of DKK83.09 for the next financial year.
What is the trend in the Genmab A/S share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genmab A/S. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -15.46%.
As of the last closing price of DKK2,006.00, shares in Genmab A/S were trading -10.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Genmab A/S PE Ratio?
The Genmab A/S PE ratio based on its reported earnings over the past 12 months is 22.01. The shares last closed at DKK2,006.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Genmab A/S?
Genmab A/S' management team is headed by:
- Deirdre Connelly - CHM
- Jan van de Winkel - CEO
- Anthony Pagano - CFO
- Anthony Mancini - COO
- Tahamtan Ahmadi - EVP
- Judith Klimovsky - EVP
- Birgitte Stephensen - SVP
- Martine van Vugt - SVP
- Rima Nassar - DRC
- Anders Pedersen - DRC
- Peter Storm Kristensen - DRC
- Mijke Zachariasse - DRC
- Pernille Erenbjerg - IND
- Rolf Hoffmann - IND
- Paolo Paoletti - IND
- Jonathan Peacock - IND